• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.

作者信息

Lee Yu-Lin, Hsueh Po-Ren

机构信息

Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Ph.D. Program in Medical Biotechnology, Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan.

Departments of Laboratory Medicine and Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan; Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

出版信息

J Infect. 2023 Jul;87(1):e1-e4. doi: 10.1016/j.jinf.2023.04.013. Epub 2023 Apr 24.

DOI:10.1016/j.jinf.2023.04.013
PMID:37100173
Abstract
摘要

相似文献

1
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.2018 - 2021年抗菌药物检测领导力与监测（ATLAS）项目结果显示，在印度，头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和美罗培南/法硼巴坦对耐碳青霉烯类铜绿假单胞菌的体外活性较差。
J Infect. 2023 Jul;87(1):e1-e4. doi: 10.1016/j.jinf.2023.04.013. Epub 2023 Apr 24.
2
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.体外研究头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、美罗培南-沃巴坦和其他对照药物对碳青霉烯类药物耐药程度不一致的铜绿假单胞菌分离株的活性：来自抗菌药物检测领导和监测（ATLAS）计划的数据，2012-2021 年。
Int J Antimicrob Agents. 2023 Aug;62(2):106867. doi: 10.1016/j.ijantimicag.2023.106867. Epub 2023 May 25.
3
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
4
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and .2017 年中国抗菌药物监测网（CHINET）对临床分离的 和 的头孢他啶-阿维巴坦和头孢唑南-他唑巴坦活性研究结果。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02431-18. Print 2019 Apr.
5
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
6
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.体外研究头孢洛扎他唑巴坦和头孢他啶-阿维巴坦对耐美罗培南铜绿假单胞菌临床分离株的活性：一项多中心研究。
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
7
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.评估头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦对来自卡塔尔的多重耐药铜绿假单胞菌分离株的体外活性。
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504. doi: 10.1093/jac/dkz379.
8
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.头孢洛扎/他唑巴坦对香港不同感染中革兰氏阴性菌分离株的活性：2017 - 2019年全球医院感染监测研究（SMART）
J Med Microbiol. 2022 Apr;71(4). doi: 10.1099/jmm.0.001487.
9
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.碳青霉烯类耐药肠杆菌科细菌和铜绿假单胞菌中头孢他啶-阿维巴坦和头孢唑南-他唑巴坦药敏检测方法的验证。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01093-17. Print 2018 Feb.
10
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.匈牙利耐多药铜绿假单胞菌中头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的药敏情况。
Acta Microbiol Immunol Hung. 2020 Mar 26;67(1):61-65. doi: 10.1556/030.2020.01152.

引用本文的文献

1
Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).在一名肾移植受者中，使用研究性抗生素头孢吡肟/齐德巴坦（WCK 5222）成功治疗了由产新德里金属β-内酰胺酶的铜绿假单胞菌引起的肺感染和颅底骨髓炎。
Eur J Clin Microbiol Infect Dis. 2024 Feb 28. doi: 10.1007/s10096-024-04791-1.
2
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.成功使用头孢吡肟-齐多夫定（WCK 5222）作为挽救疗法治疗急性 T 细胞白血病成年患者广泛耐药新德里金属β-内酰胺酶产生铜绿假单胞菌感染的播散性感染。
Antimicrob Agents Chemother. 2023 Aug;67(8):e0050023. doi: 10.1128/aac.00500-23. Epub 2023 Jun 14.